Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harrow Inc (NQ: HROW )

10.27 -0.05 (-0.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 406,168
Open 10.32
Bid (Size) 9.900 (5)
Ask (Size) 10.44 (1)
Prev. Close 10.32
Today's Range 10.04 - 10.44
52wk Range 7.600 - 27.75
Shares Outstanding 35,362,642
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Over $24M Bet On RXO? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
From Melt Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
-14.06%
-14.06%
1 Month
-14.42%
-14.42%
3 Month
+3.42%
+3.42%
6 Month
-28.38%
-28.38%
1 Year
-59.29%
-59.29%

More News

Read More
Insiders Buying Greenwich LifeSciences And 2 Other Stocks
Via Benzinga
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Harrow: Q4 Earnings Insights
Via Benzinga
INTC Stock Alert: Intel Just Got a Major $8.5 Billion Boost
Via InvestorPlace
Why Is Aquestive Therapeutics (AQST) Stock Down 14% Today?
Via InvestorPlace
Why Is Harrow (HROW) Stock Up 5% Today?
Via InvestorPlace
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Earnings Preview: Harrow Health
Via Benzinga
Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
HROW Stock Earnings: Harrow Health Misses EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
From Harrow, Inc.
Via Business Wire
Earnings Scheduled For March 19, 2024
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
From Harrow, Inc.
Via Business Wire
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
From Harrow, Inc.
Via Business Wire
Harrow Announces New Appointments to its Board of Directors
From Harrow, Inc.
Via Business Wire
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease
From Harrow, Inc.
Via Business Wire
Melt Pharmaceuticals Provides Corporate Update
From Melt Pharmaceuticals, Inc.
Via Business Wire
Harrow Partners with Leading Healthcare Market Access Technology Platforms
From Harrow, Inc.
Via Business Wire
7 Short-Squeeze Stocks That Are Screaming for Speculation
Via InvestorPlace
Harrow Completes Transfer of the TRIESENCE® New Drug Application
From Harrow, Inc.
Via Business Wire
Harrow to Present at Two Investor Conferences in November
From Harrow, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.